In NDMM, how does KRd compare to VRd regarding efficacy endpoints? Happy to share our new meta-analysis just published in AmericanJournalofHematology: doi.org/10.1002/ajh.27….

KRd-treated pts showed higher odds of achieving MRD negativity and CR/sCR compared to VRd-treated pts, while ORR,…

High physical activity is inversely associated with MGUS, whereas heavy smoking and short sleep are positively associated with MGUS. ow.ly/q8Zn50R7twS #lymphoidneoplasia

Dr. Jeffrey Zonder presents on iberdomide-dara for post-transplant maintenance #HemeDAVA

I filmed a video for PBS on screening and diagnosing multiple myeloma for primary care providers. It will air on PBS - Detroit Public Television on 4/7 at 10:30am and 4/11 at 2:30pm

Multiple Myeloma I Primary Care with Dr. Lonnie Joe - 801 youtu.be/7YDzIl3DloU?si… via YouTube

Why does ABBV-383 not require step up dosing?

Low CD3 binding affinity lowers T-cell activation antigen expression, reducing inflammatory cytokine release, lowering the risk of CRS.

This could be a game changer for bringing bispecifics to rural communities!

#DAVAWhistlerHeme

Join Dr. Craig Cole, myeloma physician at Karmanos Cancer Institute, to discover why questioning your doctor and advocating for yourself are crucial steps in managing #myeloma . youtu.be/7Zi8x4XVlXY #IMFMPOWER

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms
ow.ly/t21j50R4Asl #bloodspotlight #immunobiologyandimmunotherapy #lymphoidneoplasia #multiplemyeloma

Happy to share our publication showing that 2-weekly bortezomib is still given in >25% of all ND patients with multiple myeloma despite similar OS and PFS and higher neuropathy rates as 1-weekly administration! Gurbakhash Kaur Rahul Banerjee, MD, FACP Blood Cancer Journal
nature.com/articles/s4140…

Truth!

Exactly that - I worry the divide between those who have broad access to #myeloma drugs, and those who have limited access - is widening exponentially

I Agee that the FDA ODAC committee voting in favor of benefit-risk of Cilta-Cel in early R/R Myeloma is fantastic, but it means that we really need to make this equitable to myeloma patients regardless of income, race, ethnicity, or access to academic centers!

FDA ODAC Committee Votes Unanimously in Favor of Benefit-Risk Profile of Cilta-Cel in Early Relapsed/Refractory/Myeloma

#mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ ⁦HealthTree Foundation⁩ ⁦ASH⁩ ⁦Sylvester Comprehensive Cancer Center⁩ ⁦University of Miami⁩ onclive.com/view/fda-odac-…

Out in Blood Neoplasia!

For those with myeloma who did not receive frontline Dara, which Dara-regimen is best? Dara-Vd? Dara-Pd? Dara-Kd?

We tried to answer this question in a fun collaboration with COTA using their real world database.

sciencedirect.com/science/articl…

A #mmsm 🧵

Humbled, grateful and honored! Thank you to the awesome Heme/Onc fellows at MSU-KCI McLaren Greater Lansing!

After long last, we have published our article outlining the #innovative population health #navigation program we started Wake Forest Baptist - Comprehensive Cancer Center!!! In this article we share what it took to get this program off the ground to improve #cancerequity
ncmedicaljournal.com/article/91427-…
1/

Today is #WorldCancerDay ! Check out this Cancer Support Community film on medical mistrust that I participated in along with my colleague & #myeloma expert Craig Cole. Equity requires #truthtelling ! MVTCP CPACHE Program NCI Disparities #JustifiedMedicalMistrust #HealthEquity youtu.be/1v7k8JW34O8?si…

Thank you to #@iStopMM investigators for your work!

Balm and Gilead conference with Craig Cole speaking on #multiplemyeloma #CARTtherapy #bispecifics and #healthdisparities

At #ASH23 , Craig Cole sat down with #OncData to share his passion for improving #diversity in multiple #myeloma clinical trials and how to help raise awareness in order to address this issue both within the #community and on a #global scale.

oncdata.com/news/improving…

#mmsm